Hospital
ST. Joseph Health Northern California, LLC
ST. Joseph Health Northern California, LLC was paid $8.55M by Medicaid between Mar 2019 and Nov 2024, across 154 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoST. JOSEPH HEALTH NORTHERN CALIFORNIA, LLC
FORTUNA, CA 95540
FORTUNA, CA 95540
33aNPI1043292303assigned 11/14/2005
33bProvider typeCritical Access Hospital
28Total paid$8.55M
24GClaims195,001
24DCodes billed154
24AFirst – last monthMar 2019 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#8 of 30
Median peer was paid$3.14M
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 25,434 | $1.10M | |
| 2020 | 31,114 | $1.49M | |
| 2021 | 36,143 | $1.61M | |
| 2022 | 39,722 | $1.60M | |
| 2023 | 37,328 | $1.65M | |
| 2024incomplete | 25,260 | $1.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 16,396 | 14,274 | $2.75M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 16% | 17,002 | 15,340 | $1.35M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.9% | 10,878 | 2,501 | $419K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 1,176 | 1,160 | $367K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 3,290 | 3,058 | $262K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.6% | 670 | 668 | $224K |
| J3490 | Unclassified drugs | 2.4% | 19,067 | 9,704 | $204K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 1,027 | 995 | $202K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 4,452 | 4,122 | $172K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 2,842 | 2,554 | $168K |
| 99201 | 1.7% | 1,257 | 656 | $145K | |
| 97750 | 1.4% | 1,537 | 1,102 | $124K |
142 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,118 | $121K |
| 97139 | 1.4% | 2,932 | $117K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,345 | $108K |
| 80053 | Comprehensive metabolic panel | 1.2% | 11,820 | $105K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 2,178 | $100K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 14,218 | $88K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,533 | $78K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,451 | $71K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 477 | $70K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 782 | $69K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,938 | $68K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,159 | $58K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 610 | $57K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,601 | $52K |
| 76830 | Ultrasound, transvaginal | <1% | 504 | $46K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,703 | $45K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,331 | $44K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 308 | $43K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,585 | $42K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 185 | $34K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 273 | $33K |
| 76770 | <1% | 236 | $31K | |
| 84484 | <1% | 2,484 | $26K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,886 | $25K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 731 | $24K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 168 | $24K |
| 73030 | <1% | 535 | $22K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 131 | $21K |
| 73630 | <1% | 563 | $21K | |
| 83880 | <1% | 728 | $21K | |
| 73562 | <1% | 514 | $18K | |
| 87631 | <1% | 287 | $18K | |
| 59025 | Fetal non-stress test | <1% | 516 | $17K |
| 80061 | Lipid panel | <1% | 1,809 | $17K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,034 | $16K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 179 | $16K |
| 83690 | <1% | 2,902 | $16K | |
| 73610 | <1% | 395 | $15K | |
| 87040 | <1% | 1,246 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,150 | $15K |
| 83605 | <1% | 1,438 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,220 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,194 | $14K |
| 72100 | <1% | 265 | $13K | |
| 73110 | <1% | 315 | $12K | |
| 84439 | <1% | 1,857 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,709 | $12K |
| 97010 | <1% | 305 | $11K | |
| 81001 | <1% | 3,354 | $11K | |
| 73130 | <1% | 272 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 446 | $11K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 166 | $10K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,094 | $10K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,601 | $10K |
| 83735 | <1% | 1,371 | $8K | |
| 80305 | <1% | 683 | $8K | |
| 87186 | <1% | 865 | $7K | |
| 85610 | <1% | 1,737 | $6K | |
| 87077 | <1% | 833 | $6K | |
| 76536 | <1% | 66 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,073 | $6K |
| 81003 | <1% | 2,888 | $6K | |
| 97799 | <1% | 146 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 45 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 500 | $5K |
| 86140 | <1% | 1,233 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 248 | $4K |
| 81025 | <1% | 1,348 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 431 | $4K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 82 | $3K |
| 72040 | <1% | 81 | $3K | |
| 85379 | <1% | 439 | $3K | |
| 99460 | <1% | 55 | $3K | |
| 85652 | <1% | 1,250 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 44 | $3K |
| 84702 | <1% | 197 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 393 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 409 | $2K |
| 86003 | <1% | 26 | $2K | |
| 93971 | <1% | 13 | $2K | |
| 82962 | <1% | 763 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $2K |
| 87081 | <1% | 463 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 267 | $2K |
| 85027 | <1% | 318 | $2K | |
| 86850 | <1% | 694 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 218 | $2K |
| 83540 | <1% | 391 | $2K | |
| 87400 | <1% | 179 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 58 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 58 | $2K |
| 86780 | <1% | 150 | $1K | |
| 90715 | <1% | 25 | $1K | |
| 74018 | <1% | 45 | $1K | |
| 83550 | <1% | 232 | $1K | |
| 82550 | <1% | 245 | $1K | |
| 82077 | <1% | 85 | $1K | |
| Z9725 | <1% | 26 | $1K | |
| 86901 | <1% | 463 | $1K | |
| 86900 | <1% | 463 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 150 | $1K |
| 82607 | <1% | 97 | $1K | |
| 82728 | <1% | 111 | $1K | |
| 72110 | <1% | 13 | $975.35 | |
| 87340 | <1% | 134 | $944.69 | |
| 86803 | <1% | 85 | $867.71 | |
| 99070 | <1% | 28 | $850.00 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 22 | $780.88 |
| 96367 | <1% | 14 | $768.46 | |
| 82570 | <1% | 209 | $751.07 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 84 | $699.54 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 78 | $677.27 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 115 | $642.85 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 26 | $627.12 |
| 82746 | <1% | 45 | $561.79 | |
| 86696 | <1% | 27 | $507.76 | |
| 86695 | <1% | 27 | $432.32 | |
| 86762 | <1% | 45 | $402.46 | |
| 85730 | <1% | 85 | $359.73 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 51 | $359.48 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 48 | $355.92 |
| 73140 | <1% | 13 | $337.05 | |
| 82105 | <1% | 39 | $273.00 | |
| 80143 | <1% | 13 | $269.88 | |
| 87205 | <1% | 71 | $256.17 | |
| 80179 | <1% | 14 | $233.25 | |
| 87147 | <1% | 66 | $228.49 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $209.78 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 28 | $192.95 |
| 87070 | <1% | 28 | $164.39 | |
| 84403 | <1% | 13 | $153.63 | |
| 86141 | <1% | 16 | $143.20 | |
| 87420 | <1% | 40 | $93.60 | |
| 87088 | <1% | 14 | $87.96 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 14 | $81.04 |
| 86592 | <1% | 27 | $78.84 | |
| 82785 | <1% | 14 | $78.53 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14 | $65.52 |
| 83615 | <1% | 17 | $61.76 | |
| 84156 | <1% | 15 | $44.37 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 38 | $0.76 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Parent organizationST. JOSEPH HEALTH SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.